From images to insights: Deep spatial phenotyping reveals disease and treatment biomarkers
This webcast presents the use of a 51-plex panel that covers a range of functional and tumor microenvironment-related biomarkers
This webcast presents the use of a 51-plex panel that covers a range of functional and tumor microenvironment-related biomarkers
Learn about the power of comprehensive spatial phenotyping and its applications
Part 1: PhenoCycler-Fusion: High-parameter Single-cell Spatial Biology Read More »
In this webinar, Akoya Biosciences’ application scientists Aditya and Ning will present a framework for analyzing multiplex immunofluorescence images generated on the PhenoImager platform.
PhenoImager Data Analysis Using QuPath and Python Read More »
During this webinar, Dr. Jessica Da Gama Duarte from Olivia Newton-John Cancer Research Institute will present the protocol for the in situ interrogation and characterization of TLSs in human and murine tissue sections using Opal-tyramide signal amplification multiplex immunohistochemistry.
Tertiary Lymphoid Structures in Solid Tumours Read More »
As cancer treatment evolves with the advent of new immunotherapies, it is crucial to accurately identify which patients will respond to these treatments. The tumor microenvironment (TME) has been shown to be a key factor in determining therapeutic responses across various cancer types.
Join Akoya Biosciences for a webinar on the PhenoImager Solution, which revolutionizes spatial phenotyping for translational and clinical research with a focus on speed, scale, accuracy, and reproducibility.
During this webinar, Dr. Cecilia Lindskog, research group leader and associate professor from Uppsala University, describes how scRNA-seq, spatial proteomics, and machine learning algorithms can be used to generate high-resolution spatio-temporal maps of human tissues.
Developing a Spatio-Temporal Single-Cell Type Map of Adult Human Tissues Read More »
Endometrial cancer is the most common gynecologic malignancy diagnosed in western countries, with most cases diagnosed as low-grade, early-stage disease.
Bladder cancer (BC) is the 10th most common cancer world-wide with an estimated 570,000+ people being diagnosed in 2020.
The emergence of new immunotherapies as the first line of treatment for cancer, necessitates the development of clinically useful biomarkers to select responders that will be critical for the advancement of such treatments.